AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04049383 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CAR-20/19-T cells (5 x 10^5 CAR-20/19-T cells/kg)
Description: The investigational agent in this protocol is the CAR-20/19-T cells.CAR-20/19-T cells will be administered either fresh or thawed after cryopreservation by IV injection. Subjects will receive one of three dose levels of CAR-20/19-T cells based on the dose escalation design.~Dose Level -1: 5 x 10\^5 CAR-20/19-T cells/kg
Study NCT03857230 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Follitropin alfa (Gonal-F)
Description: During the crossover pharmacokinetic phase, after 42 days of combined oral contraceptive (ethinylestradiol and drospirenone) administration subjects with endogenous level of follicle stimulating hormone (FSH) less than 5 IU/l were randomly assigned to receive one of the following treatment sequences:~Sequence A: Single subcutaneous injection of 300 IU Primapur on study day 1, after 10 days of wash out a single subcutaneous injection of 300 IU Gonal-F.~Sequence B: Single subcutaneous injection of 300 IU US Gonal-F on study day 1, after 10 days of wash out a single subcutaneous injection of 300 IU Primapur.
Study NCT02102880 — intervention group
Intervention type: GENETIC
Group type: OTHER
Intervention: the polymerase chain reaction (PCR)
Study NCT02818426 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: UCPVax
Study NCT01920048 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Percutaneous Coronary Intervention
Study NCT01920048 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Drug Therapy for Heart Failure
Description: The optimal combination of drugs and doses for each patient will be individualized and will be determined by his/her physician, in accordance with local and international clinical practice guidelines
Study NCT01920048 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Drug Therapy for Heart Failure
Description: The optimal combination of drugs and doses for each patient will be individualized and will be determined by his/her physician, in accordance with local and international clinical practice guidelines
Study NCT01920048 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Device Therapy for Heart Failure
Description: The optimal device therapy for each patient will be individualized and will be determined by his/her physician, in accordance with local and international clinical practice guidelines. In most cases the device will be an Implantable Cardioverter Defibrillator and/or Cardiac Resynchronization Therapy.
Study NCT01920048 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Device Therapy for Heart Failure
Description: The optimal device therapy for each patient will be individualized and will be determined by his/her physician, in accordance with local and international clinical practice guidelines. In most cases the device will be an Implantable Cardioverter Defibrillator and/or Cardiac Resynchronization Therapy.
Study NCT01674348 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: P2202
Description: Novel oral drug with potent and selective 11 beta-hydroxysteroid dehydrogenase type 1 (11b-HSD1) inhibitory properties, being developed for the management of type 2 diabetes mellitus
Study NCT01674348 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT04049383 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CAR-20/19-T cells (1 x10^6 CAR-20/19-T cells/kg)
Description: The investigational agent in this protocol is the CAR-20/19-T cells.CAR-20/19-T cells will be administered either fresh or thawed after cryopreservation by IV injection. Subjects will receive one of three dose levels of CAR-20/19-T cells based on the dose escalation design.~Dose Level 0: 1 x10\^6 CAR-20/19-T cells/kg (starting dose level)
Study NCT04049383 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CAR-20/19-T cells (2.5 x10^6 CAR-20/19-T cells/kg)
Description: The investigational agent in this protocol is the CAR-20/19-T cells.CAR-20/19-T cells will be administered either fresh or thawed after cryopreservation by IV injection. Subjects will receive one of three dose levels of CAR-20/19-T cells based on the dose escalation design.~Dose Level 1: 2.5 x10\^6 CAR-20/19-T cells/kg (goal cell dose)
Study NCT04049383 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CAR-20/19-T cells
Description: The investigational agent in this protocol is the CAR-20/19-T cells.CAR-20/19-T cells will be administered either fresh or thawed after cryopreservation by IV injection. Subjects will receive one of three dose levels of CAR-20/19-T cells based on the dose escalation design.~The dose expansion dose level is still to be determined and this section will be updated.
Study NCT03366766 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given IV
Study NCT03366766 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Given IV
Study NCT03366766 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed Disodium
Description: Given IV
Study NCT03366766 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine Hydrochloride
Description: Given IV
Study NCT01279122 — intervention group
Intervention type: DEVICE
Group type: NO_INTERVENTION
Intervention: Nanoflex IOL
Description: Patients who were implanted with the Nanoflex IOL
Study NCT00520611 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Financial Incentives
Description: Participants call in their weight on daily basis. Participants must report under their daily targets to qualify for entry into lottery. Call-in weights are verified at monthly weigh-ins.
Study NCT02217280 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Injection with Gadolinium
Description: Gadavist (gadobutrol) injection is a gadolinium-based contrast agent indicated for intravenous use in diagnostic magnetic resonance imaging (MRI) in adults and children (2 years of age and older) to detect and visualize areas with disrupted blood brain barrier (BBB) and/or abnormal vascularity of the central nervous system
Study NCT00816933 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: appendectomy
Description: appendectomy according to the number of trocar
Study NCT00816933 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: appendectomy
Description: appendectomy according to the number of trocar
Study NCT01583101 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Receiving Highlighted Prompts
Description: Prompts received by physicians were highlighted.
Study NCT00520611 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Financial Incentives
Description: Participants call in their weight on daily basis. Participants must report under their daily targets to qualify to receive daily incentive. Call-in weights are verified at monthly weigh-ins.
Study NCT02749175 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cricoid force sensor monitor system
Description: Comprise of a sensor and a monitor system
Study NCT02749175 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Cricoid force sensor monitor system
Description: Comprise of a sensor and a sham monitor system
Study NCT04016038 — intervention group
Intervention type: OTHER
Intervention: a psycho-social investigation
Description: The design of this project is based partly on the UNBIASED international study and is based on an in-depth case study in a prospective and retrospective dimension of deceased cancer patients for whom sedation has been established, and this, during a given period in different care settings: home, care center, hospital and palliative care unit.
Study NCT01583101 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Receiving Non-highlighted Prompts
Description: Prompts received by physicians were not highlighted.
Study NCT04645784 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Supporting Student-Athletes Mental Wellness
Description: The module addresses: 1) managing your own mental wellness; 2) signs and symptoms of mental health problems; 3) role of student-athletes in creating a positive team environment that is supportive of mental health care seeking; 4) the role of a student-athlete in helping teammates; 5) how to identify emergency and non-emergency mental health situations.
Study NCT02743923 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: carboplatin
Description: AUC 6
Study NCT02743923 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: paclitaxel
Description: 200mg/m2
Study NCT02743923 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bevacizumab
Description: 15 mg/kg
Study NCT02743923 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pemetrexed
Description: 500 mg/m2
Study NCT02743923 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cisplatin
Description: 75 mg/m2
Study NCT04081220 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IMG-7289
Description: Single starting dose with individualized dose titrations throughout
Study NCT03301844 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Blephapad Combo
Description: Blephapad Combo is used to cleanse, soften, sooth and decongest inflamed eyelids and cilia.~The combo also presents an applicator with a heatable tablet that is applied to the eyelid in order to clean and open occluded Meibomian glands, thereby allowing the production of lipids necessary for a healthy tear film. The heatable tablet is to be used prior to cleansing with Blephapad wipes.
Study NCT03301844 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Standard treatment
Description: Standard treatment, twice daily for one month, consisting in eyelid hygiene using wet, warm gauze.
Study NCT01107808 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Calcium and Vit D
Description: ergocalciferol (vitamin D2) treatment 50,000 IU orally, weekly for 8 weeks calcium carbonate orally 1200mg daily
Study NCT01107808 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin, Vit D and Calcium
Description: ergocalciferol (vitamin D2)50,000 IU orally weekly for 8 weeks calcium carbonate orally 1200mg daily Metformin ER 1000mg daily with dinner for 7 days and then increased to a final dose of 2000mg orally, daily for the remainder of the study (7 weeks)
Study NCT03519243 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BCD-131
Description: subcutaneously monthly
Study NCT03519243 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Mircera
Description: subcutaneously monthly
Study NCT01164462 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: blood test: rapid finger-stick blood specimen test
Study NCT03808597 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Digital health promotion intervention
Description: Digital health promition related to HIV, Tuberculosis and TSCT in a digital format.
Study NCT02804139 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard care plus physical therapy
Description: Subjects attend 1 to 2 physical therapy sessions per week for 6 weeks beginning 8-10 weeks post-C section. The physical therapy program includes scar management, core retraining, and lumbar and pelvic joint mobilization.
Study NCT02804139 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Care
Description: Standard Care after C-section with no additional physical therapy.
Study NCT01312168 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Therapeutic CPAP
Description: CPAP ventilator, optimal pressure decided by CPAP manual titration, daily use at sleep, six months
Study NCT01164462 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: blood test: conventional test
Study NCT04212364 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Peer Education
Description: In this intervention, people who use opiates will be trained to be peer educators.
Study NCT04212364 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Narcan Nasal Product
Description: All study participants will be trained in how to use nasal Narcan and they will receive a nasal Narcan kit.
Study NCT04212364 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Narcan Nasal Product
Description: All study participants will be trained in how to use nasal Narcan and they will receive a nasal Narcan kit.
Study NCT03448159 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluoxetine Hydrochloride
Description: Half of the participants will take fluoxetine for a period of 15-17 weeks (depending on ramp-up period).
Study NCT03448159 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Half of the participants will take the a placebo for a period of 15-17 weeks (depending on ramp-up period).
Study NCT03448159 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise Program
Description: All participants will take part in a 12-week exercise program. The program will run 3 times/week, 1 hour/class.
Study NCT03448159 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Exercise Program
Description: All participants will take part in a 12-week exercise program. The program will run 3 times/week, 1 hour/class.
Study NCT04555902 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Postcard
Description: The postcard includes appeals to get annual mammograms and provides information for ordering a mammogram.
Study NCT04555902 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Postcard
Description: The postcard includes appeals to get annual mammograms and provides information for ordering a mammogram.
Study NCT04555902 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Small Gift
Description: Pink socks are included in the mailer. The gift increases salience of the mailer and it potentially promotes reciprocation from the recipient in the form of ordering a mammogram.
Study NCT04555902 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Small Gift
Description: Pink socks are included in the mailer. The gift increases salience of the mailer and it potentially promotes reciprocation from the recipient in the form of ordering a mammogram.
Study NCT04555902 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Loss Frame and Fear Appeals
Description: The postcard is enhanced with language that frames the situation in terms of losses. It also uses fear appeals by stating the risks of breast cancer, while also stating that a mammogram screening is an accessible way to address those risks.
Study NCT04148339 — intervention group
Intervention type: OTHER
Intervention: No Intervention
Description: There is no intervention for this study.
Study NCT02061696 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Vascular Access Device
Description: AXERA 2 Access System with Reduced Manual Compression
Study NCT02061696 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard Manual Compression
Description: Closure procedure by Manual Compression
Study NCT00981929 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tramadol
Description: 50 mg single oral dose
Study NCT04570241 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Malaria toolkit
Description: Knowledge, attitude, and practice on malaria
Study NCT03301220 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daratumumab SC: daratumumab + rHuPH20
Description: Participants will receive daratumumab SC injection (daratumumab 1800 mg + rHuPH20 \[2000 U/mL\]) once weekly for Cycles 1 and 2 (Days 1, 8, 15, and 22 of each week), every 2 weeks for Cycle 3 to Cycle 6 (Days 1 and 15), and thereafter every 4 weeks (Day 1) until 39 cycles or up to 36 months or until confirmed disease progression, unacceptable toxicity or withdrawal from the study treatment, study termination or study completion. Each cycle is 28 days in duration.
Study NCT04305444 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DTRM-555
Description: Oral once-daily administration
Study NCT03185559 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Relievion Device- Treatment Stimulation
Description: 1 Hour self-administered treatment specific occipital and supraorbital transcutaneous nerve stimulation
Study NCT03185559 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Relievion Device- Sham stimulation
Description: 1 Hour self-administered sham occipital and supraorbital transcutaneous nerve stimulation
Study NCT04247802 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Backwards Walking (BW) programme
Description: A 12 week Backwards walking programme prescribed by a registered physiotherapist and completed as part of a home exercise programme.
Study NCT04247802 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: A 12 week physiotherapy exercise programme EXCLUDING backwards walking
Study NCT01312168 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Subtherapeutic CPAP
Description: Subtherapeutic CPAP ventilator, pressure \<3 cmH2O, daily use at sleep, six months
Study NCT04242199 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INCB099280
Description: INCB099280 administered orally in 25 mg or 100 mg tablets once daily or twice daily on each day of each 28-day cycle
Study NCT04601363 — intervention group
Intervention type: DEVICE
Intervention: Patient Specific Rod
Description: Posterior spinal fusion rod
Study NCT04551807 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Modified natural cycle
Description: This treatment protocol is defined as a modified natural cycle as the participant will be instructed to (1) administer human chorionic gonadotropin (hCG) to assist with timing of the embryo transfer and (2) supplement the luteal phase with a low dose of progesterone.
Study NCT04551807 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Programmed cycle
Description: This protocol is designated as programmed because the endometrial development occurs only in association with administration of estradiol and progesterone. No ovulation occurs due to suppression of follicle development by the estradiol and the timing of the transfer is based on the number of days elapsed following initiation of exogenous progesterone.
Study NCT03248310 — intervention group
Intervention type: BEHAVIORAL
Intervention: Quality of Life Assessments
Description: Upper Limb Lymphedema (ULL-27), Lymphedema Life Impact Scale, version 2 (LLISv2), LYMQOL-Leg.
Study NCT00692939 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: autologous CD34-selected peripheral blood stem cells transplant
Description: high-dose immunotherapy followed by infusion of autologous CD34-selected peripheral blood stem cells (PBSC)
Study NCT00692939 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alemtuzumab
Description: Transplant conditioning
Study NCT00692939 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATG
Description: Transplant conditioning
Study NCT00692939 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Description: Transplant conditioning
Study NCT00692939 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thiotepa
Description: Transplant conditioning
Study NCT00692939 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Transplant conditioning
Study NCT00692939 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Mobilization
Study NCT00692939 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: G-CSF
Description: Mobilization
Study NCT00692939 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mesna
Description: Mobilization
Study NCT06766773 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Compound heating strategy
Description: After the surgery begins, a temperature monitoring device (disposable medical temperature sensor provided by the limited company) is inserted into the patient's nasopharynx to record the core temperature, while activating the water blanket and forced air heating system.
Study NCT06766773 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: perioperative mandatory warming measures
Description: perioperative mandatory warming measures
Study NCT06766617 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 75 gr Glucose
Description: 75g of anhydrous glucose dissolved in 375 ml of water (Vittel) mixed with 150mg of U-13C\]-glucose (stable isotope from Eurisotope, France). will be orally taken
Study NCT06766123 — intervention group
Intervention type: PROCEDURE
Intervention: CABG
Description: All patients underwent isolated CABG and retrospectively followed to asses ethnic disparities
Study NCT03981900 — intervention group
Intervention type: DRUG
Intervention: Tofacitinib
Description: 5 mg BID, oral administrtaion
Study NCT03981900 — intervention group
Intervention type: DRUG
Intervention: Tofacitinib
Description: tablet form 11mg once daily oral
Study NCT03400150 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: balloon
Description: balloon implantation
Study NCT03400150 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Control
Description: Control - Marking \& IMRT are standard of care for prostate cancer - there is no study-specific intervention